We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Read MoreHide Full Article
AbbVie Inc. (ABBV - Free Report) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
In the past one year, AbbVie’s shares gained 3.9%, while the Zacks classified Large-Cap Pharma industry witnessed an increase of 5.9%.
The biopharmaceutical company reported first-quarter 2017 earnings of $1.28 per share that beat the Zacks Consensus Estimate of $1.26 per share by 1.6%. Earnings grew 11% year over year.
The company posted revenues of $6.54 billion in the reported quarter, which surpassed the Zacks Consensus Estimate of $6.51 billion. Revenues also jumped 9.7% year over year. On operational basis revenue increased 10.1%.
Quarter in Detail
Humira sales on an operational basis, excluding currency impact, rose 15.8% year over year to $4.1 billion.
First-quarter net revenue from Imbruvica was $551 million, up 44.7% year over year. U.S. sales of Imbruvica were $457 million. AbbVie recorded $94 million of international profit sharing with Johnson & Johnson (JNJ - Free Report) .
Other products that delivered an impressive performance include Duodopa which showed revenue of $80 million up 22.8% on both operational and reported basis. Another product Creon reported revenue of $185 million up 19.8% and 17% on an operational and reported basis respectively.
HCV product Viekira recorded sales of $263 million, down 15.4% sequentially.
Adjusted SG&A expenses rose 0.7%, while R&D expenses increased 23.3% in the quarter. Adjusted operating margin was 42.3% of sales in the reported quarter.
2017 Outlook
AbbVie reiterated its previously issued outlook for 2017. The company maintains its adjusted EPS in the range of $5.44–$5.54 reflecting growth of 13.9% at the mid-point.
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Heska Corporation and Galena Biopharma, Inc. which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings per share estimates increased from $1.53 to $1.65 for 2017 and from $1.80 to $2.01 for 2018, over the last 60 days. The company posted positive surprises in three of the four trailing quarters with an average beat of 291.54%.
Galena’s loss per share estimates narrowed from $2.03 to 58 cents for 2017, over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 53.83%.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y
AbbVie Inc. (ABBV - Free Report) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
In the past one year, AbbVie’s shares gained 3.9%, while the Zacks classified Large-Cap Pharma industry witnessed an increase of 5.9%.
The biopharmaceutical company reported first-quarter 2017 earnings of $1.28 per share that beat the Zacks Consensus Estimate of $1.26 per share by 1.6%. Earnings grew 11% year over year.
The company posted revenues of $6.54 billion in the reported quarter, which surpassed the Zacks Consensus Estimate of $6.51 billion. Revenues also jumped 9.7% year over year. On operational basis revenue increased 10.1%.
Quarter in Detail
Humira sales on an operational basis, excluding currency impact, rose 15.8% year over year to $4.1 billion.
First-quarter net revenue from Imbruvica was $551 million, up 44.7% year over year. U.S. sales of Imbruvica were $457 million. AbbVie recorded $94 million of international profit sharing with Johnson & Johnson (JNJ - Free Report) .
Other products that delivered an impressive performance include Duodopa which showed revenue of $80 million up 22.8% on both operational and reported basis. Another product Creon reported revenue of $185 million up 19.8% and 17% on an operational and reported basis respectively.
HCV product Viekira recorded sales of $263 million, down 15.4% sequentially.
Adjusted SG&A expenses rose 0.7%, while R&D expenses increased 23.3% in the quarter. Adjusted operating margin was 42.3% of sales in the reported quarter.
2017 Outlook
AbbVie reiterated its previously issued outlook for 2017. The company maintains its adjusted EPS in the range of $5.44–$5.54 reflecting growth of 13.9% at the mid-point.
AbbVie Inc. Price, Consensus and EPS Surprise
AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote
Zacks Rank & Key Picks
AbbVie currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Heska Corporation and Galena Biopharma, Inc. which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings per share estimates increased from $1.53 to $1.65 for 2017 and from $1.80 to $2.01 for 2018, over the last 60 days. The company posted positive surprises in three of the four trailing quarters with an average beat of 291.54%.
Galena’s loss per share estimates narrowed from $2.03 to 58 cents for 2017, over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 53.83%.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>